Open AccessDevelopment and in vitro study of a bi-specific magnetic resonance imaging molecular probe for hepatocellular carcinoma
Author(s) -
Xiaohong Ma,
Shuang Wang,
Si-Yun Liu,
Kun Chen,
Zhiyuan Wu,
Dengfeng Li,
Yong-Tao Mi,
Linping Hu,
Zhongwei Chen,
Xinming Zhao
Publication year - 2019
Publication title -
world journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.427
H-Index - 155
eISSN - 2219-2840
pISSN - 1007-9327
DOI - 10.3748/wjg.v25.i24.3030
Subject(s) - hepatocellular carcinoma , magnetic resonance imaging , antigen , antibody , iron oxide nanoparticles , cancer research , chemistry , molecular imaging , in vitro , medicine , nanoparticle , materials science , nanotechnology , biology , in vivo , immunology , radiology , biochemistry , microbiology and biotechnology
Hepatocellular carcinoma (HCC) ranks second in terms of cancer mortality worldwide. Molecular magnetic resonance imaging (MRI) targeting HCC biomarkers such as alpha-fetoprotein (AFP) or glypican-3 (GPC3) offers new strategies to enhance specificity and help early diagnosis of HCC. However, the existing iron oxide nanoparticle-based MR molecular probes singly target AFP or GPC3, which may hinder their efficiency to detect heterogeneous micro malignant HCC tumors < 1 cm (MHCC). We hypothesized that the strategy of double antibody-conjugated iron oxide nanoparticles which simultaneously target AFP and GPC3 antigens may potentially be used to overcome the tumor heterogeneity and enhance the detection rate for MRI-based MHCC diagnosis.